Abstract
For patients with chronic obstructive pulmonary disease (COPD) at risk for exacerbation, the 2016 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend either the combination of a long-acting β-agonist (LABA) plus an inhaled glucocorticoid (ICS) or monotherapy with a long-acting muscarinic antagonist (LAMA). Although some studies have shown that ICS use is associated with fewer exacerbations (especially in patients with eosinophilia …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
